PharmacoMRI of Parkinson Disease

Study Overview
=================
Brief Summary
-----------------
Based on studies showing better responsiveness of motor versus cognitive symptoms to Parkinson's Disease medication, also known as dopaminergic treatments, the investigators hypothesize that comparison of resting state networks in the on versus off medication state in Parkinson's Disease patients will show greater effects on brain networks associated with motor control.

Detailed Description
-----------------
Subject participation includes two 25-30 minute MRI scans. The subject will arrive in the off state (PD medications withheld for approximately 12 hours prior to the scan). Following the initial scan, the subject will receive 125% of his or her usual daily morning dose of PD medications which is calculated as levodopa dose equivalents (LDE) and is given as carbidopa-levodopa. The subject will then wait for an hour allowing for the medication to begin working. During this time the subject will complete cognitive assessments, questionnaires regarding the history and current state of PD, and motor assessments. The subject will then undergo a second MRI scan of approximately 25-30 minutes. The subject after completing the second MRI scan is free to leave. The entire study is approximately 2 and 1/2 hours long.

Official Title
-----------------
A Pilot Study of the Drug Effects on Brain Connectivity of Parkinson's Disease

Conditions
-----------------
Parkinson's Disease

Intervention / Treatment
-----------------
* Drug: Carbidopa-Levodopa


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Idiopathic Parkinson's Disease (PD) Older than 30 years of age at the time of diagnosis Hoehn and Yahr stage greater than or equal to 2.5 PD duration greater than 3 years Stable regimen of PD medications for at least 2 weeks prior to imaging PD medications include carbidopa-levodopa Exclusion Criteria: Patients with a diagnosis of other neurodegenerative conditions Patients unwilling or unable to give informed consent Contraindications (cardiac pacemaker, etc.) or inability (e.g., claustrophobia) to undergo MRI scan

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: On / Off medication<br>Subjects undergo MRI scanning in the medication off state and 1 hour after receiving medications. | Drug: Carbidopa-Levodopa<br>* Equivalent amount of carbidopa-levodopa will be provide to you<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation Coefficient Between UPDRS III Score and Independent Components Analysis Network Strength in Left Parietal Cortex. | Correlation coefficient between UPDRS III score and independent components analysis network strength in left parietal cortex. UPDRS III is the Unified Parkinson's Disease Rating Scale composite motor score. | 1 hour |